Wegovy HD vs Zepbound: Weight Loss, Side Effects, Cost

Wegovy HD or Zepbound: which one leads to more weight loss? Here is the short answer. Nobody has tested them side by side. Wegovy HD, the 7.2 mg dose of semaglutide, averaged 18.8% weight loss in its 72-week trial. Zepbound 15 mg averaged 20.9% in its own 72-week trial. In September 2026, Eli Lilly presented an indirect comparison of the two that put Zepbound 15 mg ahead, but by how much depends on the method. This guide lays out the numbers from the official labels, what Lilly's analysis does and does not show, the side effects, and the prices.

Wegovy HD vs Zepbound at a glance

Weight-loss figures are from the intention-to-treat tables in each FDA label, which count everyone who was randomized.

What is Wegovy HD?

Wegovy HD is not a new drug. It is a higher dose of the same semaglutide in regular Wegovy. Regular Wegovy tops out at 2.4 mg a week. The label now says that if you have tolerated 2.4 mg for at least 4 weeks and more weight loss is needed, the dose may go up to a maximum of 7.2 mg. That 7.2 mg pen is sold as Wegovy HD. It holds 0.75 mL, the same volume as the 2.4 mg pen.

A few limits matter. The label says 7.2 mg has not been studied in teens, so teens stay at 2.4 mg or lower. For the heart-risk and MASH (fatty liver) uses, the dose stays at 2.4 mg. Our semaglutide dosage chart shows every Wegovy and Ozempic step in one place.

How much weight do you lose on Wegovy HD vs Zepbound?

These are the results from each drug's main 72-week trial, as printed in the labels.

The STEP UP paper also reported 20.7% weight loss for people who stayed on Wegovy HD as planned. In SURMOUNT-1, the comparable number for Zepbound 15 mg was 22.5%. On both measures, Zepbound is about 2 points ahead.

But these were two different trials. They enrolled different people, at different times, with different starting weights. You cannot read a winner from two separate trials with full confidence. That is why the next part matters.

What did Lilly's indirect comparison find?

On September 29, 2026, Lilly announced an analysis presented at the EASD meeting in Milan. It used a statistical method called multilevel network meta-regression to compare SURMOUNT-1 with STEP UP. It adjusted for sex, age, starting weight and starting A1C. Here is what it reported.

How to read this:

• The 4.5-point headline comes from the method that counts everyone, including people who stopped the drug. That number reflects real-world staying power as much as the drug itself.
• Among people who kept taking the drug, the gap shrank to 1.8 points, and the statistics could not rule out no difference at all.
• Lilly paid for and ran the analysis. It has not been published as a full journal paper yet, and Novo Nordisk did not take part.
• Lilly's own release says there is no head-to-head trial of tirzepatide 15 mg against semaglutide 7.2 mg.

The older head-to-head trial, SURMOUNT-5, compared Zepbound with regular Wegovy (up to 2.4 mg), not Wegovy HD. We cover it in semaglutide vs tirzepatide.

Wegovy HD side effects vs Zepbound side effects

Both drugs mostly cause stomach side effects, and both are worst during dose increases. The tables below are from the FDA labels. The Wegovy HD numbers come from the 7.2 mg trials. The Zepbound numbers come from its weight-loss trials at 15 mg.

The Wegovy HD table only lists effects that were more common on 7.2 mg than on 2.4 mg and placebo, so a blank does not mean an effect never happened. The trials also differed, so small gaps are not a fair ranking.

The one clear standout is dysesthesia: a tingling, burning, prickly or extra-sensitive skin feeling. The label says it showed up in 22% of people on 7.2 mg. Most cases got better, often after the dose was paused or lowered. About 18% of people who had it had not recovered by the end of the trial. If you notice odd skin sensations on Wegovy HD, tell your prescriber rather than changing your dose yourself. Our Wegovy skin burning guide covers what it feels like and how often it comes back. For stomach side effects, our nausea guide has practical tips.

Protecting muscle at the highest doses

More weight loss is not only fat. Trials that scanned body composition on these drugs found that a real share of the weight lost came from lean mass, which includes muscle. At the top doses of either drug, you lose more weight, and appetite is lower, so it is easier to under-eat protein.

Two habits help most: eat enough protein every day and do regular strength training. Sharpy sets one protein target sized to you, gives you one 20-minute workout a day, and tracks a Shape Score, so you can see if you are losing fat and not muscle. Our protein target guide explains how much you need.

Wegovy HD cost vs Zepbound cost

Prices change often. These are the self-pay prices we checked in late October 2026.

With insurance, your cost depends on the plan. Many plans require prior authorization for weight-loss drugs, and some do not cover them at all. Ask your plan whether the 7.2 mg dose of Wegovy is covered, since a plan that covers Wegovy may still have its own rules for the higher dose. For the details on each program, see LillyDirect Zepbound and NovoCare Pharmacy.

Wegovy HD vs Zepbound: which is better for you?

There is no single winner. Here are the questions to bring to your prescriber:

• Are you already on Wegovy 2.4 mg and doing well? Wegovy HD is the next step on the same drug. That is the path its label describes.
• Have you stalled on Wegovy 2.4 mg? Your doctor may weigh Wegovy HD against switching to Zepbound. Lilly's analysis suggests Zepbound 15 mg may have a small edge, but it is not proven in a direct trial.
• Do you have sleep apnea, heart disease or MASH? The approved uses differ. Zepbound is approved for sleep apnea. Wegovy is approved for heart-risk reduction and MASH at 2.4 mg.
• How did side effects go so far? If skin sensitivity worries you, the 22% dysesthesia rate on Wegovy HD is worth discussing.
• What will your insurance pay? Coverage often decides this more than trial results.

Do not change doses or switch drugs on your own. That decision belongs to you and your prescriber.

The bottom line

Wegovy HD closes much of the gap with Zepbound, but Zepbound 15 mg still came out a bit ahead in each drug's own trial and in Lilly's indirect comparison. The gap is small, and it has not been tested head to head. Side effects differ, especially the skin-tingling effect seen with Wegovy HD, and self-pay prices are within $50 a month. Whichever you choose, the habits that protect muscle are the same. Sharpy keeps them simple: one protein target, one 20-minute workout and one Shape Score a day.

Sources

• Wegovy (semaglutide) injection and tablets prescribing information, rev. June 2026 (DailyMed)
• Zepbound (tirzepatide) prescribing information, rev. August 2026 (DailyMed)
• Eli Lilly: Zepbound was associated with more weight loss than Wegovy HD in a new indirect treatment comparison (PR Newswire, Sep 29, 2026)
• Healio: STEP UP high-dose semaglutide led to 21% weight loss for adults with obesity
• AJMC: Higher-dose semaglutide approved (March 20, 2026)
• Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1), NEJM 2022